Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 18, Issue 12, Pages 749-750
http://dx.doi.org/10.1155/2004/742140
Canadian Gastroenterology Elsewhere

Cost-Effectiveness of Intravenous Proton Pump Inhibitors in High-Risk Bleeders

Sander Veldhuyzen van Zanten

Division of Gastroenterology, Dalhousie Medical School, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

There is unequivocal evidence that proton pump inhibitors (PPIs) are currently the most effective acid suppressive agents available. Intravenous (IV) formulations have been developed, although only IV pantoprazole is available in Canada. In patients presenting with serious upper gastrointestinal (GI) bleeding due to duodenal or gastric ulcers, it has always been believed that IV administration of acid-lowering agents would improve clinical outcomes. The reason behind this thinking is twofold. First, there is in vitro evidence that formed clots are more stable at or near neutral pH (1). Second, by administering the agent intravenously, suppression of acid production is achieved much more quickly, thereby promoting more rapid healing of the ulcer and reducing the risk of persistent or recurrent bleeding. Interestingly and surprisingly, however, the data for intravenous H2-blockers have been disappointing (2). This failure to demonstrate clinical benefit has never been fully explained.